Your Good Partner in Biology Research
Your Good Partner in Biology Research
Antibody drug refers to the preparation of antibody engineering technology based on cell and genetic engineering technology. It has high specificity, effectiveness and safety in binding to the target antigen. It is clinically used for major diseases such as malignant tumors and autoimmune diseases.
The research and development of antibody drugs, from the initial determination of the target, to the screening of lead molecules, preclinical research, to entering the clinical phase trial, and completing the final NDA declaration, it takes 10 years to complete the entire process. Throughout the entire new antibody drug development process, the lead antibody molecule is the beginning of the story. It can be said that companies that can develop lead molecules for specific targets basically get tickets for new drug research and development. CUSABIO has been committed to the development and production of proteins and antibodies, and can provide a one-stop service for your early discovery of lead antibody molecules and accelerate your drug development process.
● Five traditional recombinant protein and three featured transmembrane protein expression systems are suitable for expressing proteins of different properties, and can meet different customers' demands.
CUSABIO has 15 years of experience in recombinant protein expression and can provide one-stop services from gene synthesis, vector construction to protein expression and purification. Based on the traditional five recombinant protein expression systems (E. coli, Yeast, Insect Baculovirus, Mammalian cell and In vitro E.coli systems.), CUSABIO has now launched four dominant protein expression platforms for drug target proteins, namely Virus-like Particles (VLPs), Detergent Micelle, Nanodisc and Nanoparticle platforms.
Antibody drug analogue refers to drug control antibody. The priority order of antibody drug analogue sequence reference is as follows: marketed antibody drugs, clinical stage (Ⅰ-Ⅲ) antibody drugs, preclinical stage antibody drugs, and FACS antibodies.
Stable cell line refers to a cell line that continuously and stably expresses or interferes with the expression of a specific gene through stable transduction. In the field of antibody development, stable transfected cell lines can be used as immunogens to stimulate specific immune responses in animals, and can target multiple transmembrane proteins. In addition, stable transfected cell lines are widely used in antibody binding and functional screening experiments. CUSABIO can provide stable cell line construction service, and the specific service content are as follows:
| Lentivirus Packaging and Construction of Stable Cell Service | |||
| No. | Process | Service Items | Service Cycle |
|---|---|---|---|
| 1 | Construction of recombinant plasmid | Codon optimization, full gene synthesis, construction of lentiviral expression vector, large-scale extraction of plasmids | 2-3 weeks |
| 2 | Lentiviral packaging | Co-transform the expression vector and helper plasmid into 293T cells for lentivirus packaging | 1-2 weeks |
| 3 | Cell pool screening and verification | Screen the positive cells with the corresponding screening agent, and detect the expression level of the cell pool | 1-2 weeks |
| 4 | Monclonal stable cell screening and verification | Plate single cells and verify the expression of monclonal stable cell | 3-4 weeks |
| 5 | Monclonal stable cell cryopreservation and QC | Monclonal stable cell expansion culture, cryopreservation, resuscitation detection viability rate and microbial contamination | 1-2 weeks |
| Total time | 8-12 weeks | ||
CUSABIO can provide a variety of immune animals to meet the different needs of different customers.
Multiple antigens (small molecular weight protein, ECD, full-length antigen, VLP antigen, stable transfected cells, etc.), multiple hosts (mouse, rat, rabbit, alpaca, etc.), multiple adjuvants (Freund's adjuvant, Rapid adjuvant) is optional; there are special immunization programs for cell and VLP antigen immunization, which can enhance the immune response and increase the antibody titer.
CUSABIO has 15 years of rich experience in the development of hybridoma monoclonal antibodies with mature technical routes, stable and reliable product quality and high success rate. The initial positive rate is as high as about 20%-40%, and the flow positive rate is about 10%-20%, which can meet the needs of different types of customers.
CUSABIO has several native phage display libraries with capacity of 1011, including alpaca native library, humanized nano library, human library, mouse library. The correct insertion rate of CUSABIO libraries can be as high as 100%, and the positive rate of screening can be above 90%. So we can provide rapid screening service, and finish the antibody screening within 2-4 weeks at the fastest as well, the antibody affinity can reach the level of nM. CUSABIO can offer the services of antibody humanization and affinity maturation to our customers.
For the lead molecule antibodies obtained through screening, CUSABIO will further perform antibody function detection according to customer needs, including antigen ELISA, cell FACS, antigen SPR and antigen binning Antigen ELISA and antigen SPR mainly detect the binding activity and affinity of antigen and antibody, cell FACS detects the binding activity of antibody and cell, and antigen binning test identifies whether the selected lead antibody molecule and the antigen epitope recognized by the positive antibody are consistent.
